Mark Fitzgerald

Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold

Steven D. Forman, Jonathan D. Cohen, Mark Fitzgerald et al. · Magnetic Resonance in Medicine · 1995 · 3.2K citations

Medicine, Biostatistics, Neuroscience +16

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 406 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Jienchi Dorward, Ly‐Mee Yu et al. · The Lancet · 2021 · 318 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 310 citations · Full text

Pharmacy, Community Medicine, Pharmacotherapy +14

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

Hesham Abdelhady, Marwa Abdelrazik, Zakee Abdi et al. · JAMA · 2021 · 212 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +11